CME Group (NASDAQ:CME - Get Free Report) had its target price raised by stock analysts at Barclays from $219.00 to $231.00 in a report released on Thursday, Benzinga reports. The firm currently has an "equal weight" rating on the financial services provider's stock. Barclays's price objective indicates a potential upside of 1.70% from the company's current price.
A number of other analysts have also commented on CME. Keefe, Bruyette & Woods boosted their price target on shares of CME Group from $212.00 to $213.00 and gave the company a "market perform" rating in a research note on Thursday, July 25th. Morgan Stanley upped their price target on CME Group from $210.00 to $233.00 and gave the stock an "equal weight" rating in a report on Thursday, October 17th. The Goldman Sachs Group raised their price objective on CME Group from $195.00 to $198.00 and gave the company a "sell" rating in a research note on Thursday, October 3rd. Citigroup upped their target price on shares of CME Group from $240.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, October 3rd. Finally, Piper Sandler boosted their price target on shares of CME Group from $225.00 to $240.00 and gave the stock an "overweight" rating in a report on Tuesday, October 8th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $220.87.
Get Our Latest Report on CME
Shares of CME opened at $227.14 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.02 and a quick ratio of 1.02. CME Group has a 1 year low of $190.70 and a 1 year high of $230.12. The business has a 50-day moving average of $218.08 and a 200-day moving average of $208.66. The company has a market capitalization of $81.79 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 7.76 and a beta of 0.55.
CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.03. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The company's revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.25 earnings per share. As a group, equities research analysts anticipate that CME Group will post 10.04 earnings per share for the current year.
In related news, Director Bryan T. Durkin sold 7,593 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the sale, the director now directly owns 55,607 shares in the company, valued at approximately $11,932,706.13. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other CME Group news, Director Bryan T. Durkin sold 7,593 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the sale, the director now owns 55,607 shares of the company's stock, valued at $11,932,706.13. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Lynne Fitzpatrick sold 754 shares of the firm's stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the transaction, the chief financial officer now directly owns 13,261 shares of the company's stock, valued at $2,877,504.39. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company's stock.
Several institutional investors have recently made changes to their positions in CME. Capital International Investors raised its stake in CME Group by 24.1% in the first quarter. Capital International Investors now owns 15,809,175 shares of the financial services provider's stock valued at $3,403,557,000 after purchasing an additional 3,069,806 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of CME Group by 11.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,283,196 shares of the financial services provider's stock valued at $1,038,676,000 after buying an additional 537,758 shares in the last quarter. GUARDCAP ASSET MANAGEMENT Ltd lifted its holdings in shares of CME Group by 1.1% during the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 4,009,068 shares of the financial services provider's stock worth $863,112,000 after acquiring an additional 43,293 shares during the last quarter. Raymond James & Associates grew its position in CME Group by 3.2% in the second quarter. Raymond James & Associates now owns 3,029,145 shares of the financial services provider's stock worth $595,530,000 after acquiring an additional 94,302 shares in the last quarter. Finally, Legal & General Group Plc grew its position in CME Group by 6.6% in the second quarter. Legal & General Group Plc now owns 2,835,075 shares of the financial services provider's stock worth $557,371,000 after acquiring an additional 176,004 shares in the last quarter. Institutional investors own 87.75% of the company's stock.
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.